The Officers include the Board Chair, President, Health Care & Education, President, Medicine & Science, Secretary/Treasurer, and the Chief Executive Officer.
Umesh Verma is chief executive officer of BLUE LANCE, Inc., a leading developer of cybersecurity governance, assurance, audit, and compliance automation software. He is the founder of Cyber Houston and the Houston Cyber Summit. A national leader in emerging technologies, Verma serves on the Boards of The Center for Houston's Future, University of Houston College of Technology, and the Greater Houston HealthConnect. Verma is passionate about helping improve the lives of people with diabetes and serves on the executive committee of the Houston Diabetes Resource Center. Verma has served the American Diabetes Association as chair of the Houston Community Leadership Board, Chair of the Finance Committee, and as the 2017 secretary/treasurer for the national board of directors.
Tracey D. Brown is Chief Executive Officer of the American Diabetes Association (ADA), the nation’s largest voluntary health organization and a global authority on diabetes.
Tracey joined the ADA in June 2018 after her tenure as senior vice president of operations and chief experience officer at Sam's Club, a division of Walmart, Inc., where she was responsible for creating meaningful member experiences, directing member strategy, marketing and branding, go-to-market execution, data and analytics and membership operations.
Tracey brings more than 25 years of experience in driving global business growth, leveraging data to connect consumers with brands and creating omni-channel experiences to escalate customer loyalty. Prior to joining Sam’s Club, Tracey was chief executive officer and managing director of RAPP Dallas, a data-driven integrated marketing agency. Before RAPP, she served as chief operating officer for direct marketing agency Direct Impact, where she coordinated strategic, tactical and overall company operations.
Previously, Tracey was director of worldwide consumer marketing for Advanced Micro Devices, where she drove global marketing and demand generation activity around the world, including China, India, Russia, France, Spain, Italy and Japan. Early in her career, she served in leadership positions at American Express, Proctor & Gamble and Exxon Mobil.
Tracey earned a master of business administration degree from Columbia Business School in New York and a bachelor of chemical engineering degree from the University of Delaware.
Tracey, who lives with type 2 diabetes, recently served as a volunteer and fundraiser for the ADA in her local community. She joined the ADA’s National Board of Directors in January 2018, before transitioning to her new role as CEO. She and her family resides in the Washington, D.C. metropolitan area.
Robert Eckel is a distinguished Alumnus of the University of Cincinnati College of Medicine; Professor of Medicine Emeritus with appointments in the Division of Endocrinology, Metabolism and Diabetes and Division of Cardiology, and former Charles A. Boettcher II Endowed Chair in Atherosclerosis at the University of Colorado School of Medicine Anschutz Medical Campus. He also was a member of the Scientific Advisory Council of the National Institute of Diabetes, Digestive and Kidney Diseases at the National Institutes of Health. In addition, he served as President of the North American Association for the Study of Obesity and President of the American Heart Association.
Mary de Groot, Ph.D., is an Associate Professor of Medicine and Acting Director of the Diabetes Translational Research Center at Indiana University. She received her Master of Education degree from the Harvard University Graduate School of Education in 1989 and her doctorate in Clinical Psychology from the University of Rhode Island in 1999. Dr. de Groot is a clinical health psychologist whose research focuses on examining the mechanisms that link diabetes and depression as well as the development of accessible interventions to treat depression among adults and socioeconomically and culturally diverse populations with diabetes. Since 2017, Dr. de Groot is a member of the American Diabetes Association National Board of Directors.
Martha Parry Clark is a retired CEO with global executive experience that spans the asset management, health non-profit, banking, and strategy consulting industries. For the American Diabetes Association, Clark serves as Chair of the Finance Committee, and served previously as interim Chief Executive Officer, and as Chair of the Community Leadership Board for the San Francisco Bay Area. She also serves as Co-Chair of Project Redwood, a non-profit that provides grants and advisory services to early-stage social entrepreneurs focusing on extreme poverty.
C. Ronald Kahn is an internationally known diabetes researcher whose focus is understanding the mechanism of insulin action and the insulin resistance of type 2 diabetes and obesity. He currently serves as Mary K. Iacocca Professor of Medicine at the Harvard Medical School; and Chief Academic Officer and Head, Section of Integrative Physiology and Metabolism, at the Joslin Diabetes Center. From 1981 until 2000, Kahn was the Research Director of Joslin and from 2000 to 2007 served as President. Under his leadership, Joslin research grew more than 20-fold, clinical and educational activity tripled, and new corporate alliances were launched. He has held memberships on many national commissions and committees, including the Research Policy and Finance Committees of the ADA and chairing the congressionally mandated Diabetes Research Working Group, which developed the strategic plan for diabetes research in the United States. Dr. Kahn also was the Associate Review Editor of Diabetes Care from 1990-1992.
Cynthia E. Muñoz, PhD, MPH, is Assistant Professor of Clinical Pediatrics at the Keck School of Medicine of USC (the University of Southern California) in Los Angeles, where she provides clinical care to children, youth and families with diabetes through the Children’s Hospital Los Angeles (CHLA) Center for Endocrinology, Diabetes and Metabolism (CEDM) Embedded Psychology Program and the CHLA Behavioral Health Center. A licensed psychologist who is bilingual and serves patients in both English and Spanish, Dr. Muñoz co-developed a psychoeducational and skills-based program, TEEN POWER, for adolescents with insulin-treated diabetes, their siblings and their caregivers. TEEN POWER is now offered through the CHLA Behavioral Health Center and the CEDM and targets a diverse population, including adolescents in the foster care system.
Christopher K. Ralston, JD, is a partner and deputy practice coordinator in the New Orleans litigation practice at Phelps Dunbar LLP. Mr. Ralston handles a range of commercial litigation and focuses in the areas of antitrust law, business torts, trade secret litigation and contract disputes, tax litigation, securities litigation and arbitration, direct selling and intellectual property litigation. He also serves as a part of the firm’s appellate practice. Mr. Ralston’s work in the legal field has received recognition in numerous forms: in 2009, he received the Louisiana State Bar Association’s Friend of Pro Bono Award; in 2012, he was named to the New Orleans City Business Hall of Fame; and in 2016, he received both the Federal Bar Association’s New Orleans Chapter President’s Award and the Louisiana State Bar Association’s President’s Award. After recognizing the devastating impact of diabetes in New Orleans, Mr. Ralston joined the ADA’s New Orleans Community Leadership Board (CLB) in 2009, and he has served as Chair of the CLB since 2014.
As President of Terminals for Kinder Morgan, Inc., Mr. Schlosser oversees the largest independent network of liquids and bulk terminals in North America. Kinder Morgan's terminals have approximately 88 million barrels of liquids capacity and handle about 100 million tons of bulk materials annually. The liquids terminals store petroleum products and chemicals and the bulk facilities store and handle coal, petroleum coke and other materials. Additionally, the Terminals business owns Jones Act product tankers that are engaged in the marine transportation of crude oil, condensate and refined products in the United States. Kinder Morgan Terminals generates approximately $20B in annual revenue and $1.2B in annual EBITDA.
Mr. Schlosser holds a Bachelor of Science degree in science from Miami University, Oxford, Ohio. He is a past chairman and member of the Houston Chapter’s American Diabetes Association. He also serves on the board of directors for the Greater Houston Port Bureau and on the board of the Kinder Morgan Foundation. Mr. Schlosser has two children, Elizabeth and Clay.